Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
Mainak BanerjeeIndira MaisnamRimesh PalSatinath MukhopadhyayPublished in: European heart journal (2023)
MRAs did not influence SGLT2i effects on the composite of HHF/CVD, HHF or all-cause mortality; however, findings hinted at a more pronounced relative reduction in CVD in chronic HF patients regardless of EF who were randomized to SGLT2i and receiving an MRA compared to those randomized to SGLT2i and not receiving MRAs. SGLT2i attenuated the risk of MRA-associated treatment-emergent hyperkalaemia. These findings warrant further validation in well-designed randomized controlled trials.
Keyphrases
- heart failure
- double blind
- open label
- end stage renal disease
- placebo controlled
- randomized controlled trial
- ejection fraction
- phase iii
- newly diagnosed
- prognostic factors
- contrast enhanced
- clinical trial
- peritoneal dialysis
- magnetic resonance imaging
- magnetic resonance
- replacement therapy
- cardiac resynchronization therapy
- smoking cessation
- drug induced